Table 4.
Base case analysis results for 1 million Japanese adults aged ≥ 65 years vaccinated with RZV vs. no vaccine
| Outcome | RZV | No vaccine | RZV vs. no vaccine | |
|---|---|---|---|---|
| Health outcomes | ||||
| HZ cases | 152,103 | 201,086 | (48,983) | |
| PHN cases | 41,420 | 53,556 | (12,136) | |
| Complication cases | 15,672 | 20,590 | (4918) | |
| Death due to HZ | 35 | 42 | (7) | |
| Costs (discounted) | ||||
| Vaccination costs | ¥12,879,004,440 | ¥0 | ¥12,879,004,440 | |
| Direct costs due to HZ | ¥8,588,964,332 | ¥11,479,632,318 | (¥2,890,667,986) | |
| Indirect costs due to HZ | ¥1,897,343,257 | ¥2,546,279,452 | (¥648,936,196) | |
| QALYs (discounted) | ||||
| QALYs gained | 12,589,913 | 12,587,599 | 2314 | |
| Cost-effectiveness | ||||
| ICER | ||||
| Payer | – | – | ¥4,316,457/QALY | |
| Societal | – | – | ¥4,036,020/QALY | |
HZ herpes zoster, ICER incremental cost-effectiveness ratio, PHN postherpetic neuralgia, QALY quality-adjusted life years, RZV recombinant zoster vaccine, () refers to savings